Lonza Group Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Lonza Group Stock Forecast and Price Target
If the average price target of CHF516.00 set by eight distinguished experts for Lonza Group over the past few weeks is reached this year, there would be a potential upside of approximately 12.61% from the last closing price in March, 2024. This potential increase is based on a high estimate of CHF635.00 and a low estimate of CHF375.00. Even if you are not interested in LONN stock, you should still be aware of its competitors.
12.61% Upside
Lonza Group Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Lonza Group's Price has decreased from CHF466.85 to CHF0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach CHF376.11 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$599.43 | Buy/Sell | $591.94 | 0.10% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
DHR Stock Forecast | Danaher | Outperform |
10
|
$252.80 | Buy/Sell | $260.33 | 2.85% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
BP. Stock Forecast | BP p.l.c. | Outperform |
9
|
£4.72 | Buy/Sell | £7.50 | 60.59% |
Lonza Group Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Lonza Group's Revenue has grown, rising from CHF4.51B to CHF6.72B – a growth of 49.00%. In the following year, 19 experts forecast that Lonza Group's Revenue will decrease by 2.49%, to CHF6.55B. For the next seven years, the forecast is for Revenue to grow by 86.49%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$239.50 | Buy/Sell | $284.47 | 16.91% |
IQV Stock Forecast | IQVIA Holdings | Outperform |
15
|
$258.58 | Buy/Sell | $267.27 | 6.35% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
Lonza Group Dividend per Share Forecast for 2023 - 2025 - 2030
Lonza Group's Dividend per Share has grown In the last two years, rising from CHF3.00 to CHF3.50 – a growth of 16.67%. In the next year, analysts believe that Dividend per Share will reach CHF4.30 – an increase of 22.86%. For the next seven years, experts predict that Lonza Group's Dividend per Share will grow at a rate of 200.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩830.00k | Buy/Sell | ₩0.00B | 26.51% |
DOW Stock Forecast | Dow | Hold |
2
|
$57.43 | Buy/Sell | $57.75 | -2.49% |
GIVN Stock Forecast | Givaudan | Hold |
14
|
CHF3.94k | Buy/Sell | CHF3.14k | -16.22% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LYB Stock Forecast | LyondellBasell Industries NV | Hold |
14
|
$100.66 | Buy/Sell | $103.00 | -0.66% |
BAYN Stock Forecast | Bayer | Hold |
5
|
26.82€ | Buy/Sell | 45.15€ | 26.77% |
CAH Stock Forecast | Cardinal Health Inc | Hold |
13
|
$115.48 | Buy/Sell | $108.07 | -0.42% |
Lonza Group EBITDA Forecast for 2023 - 2025 - 2030
Lonza Group's EBITDA has decreased by 0.22% In the last three years, from CHF1.39B to CHF1.39B. For the next year, analysts predict that EBITDA will reach CHF1.84B – an increase of 32.60%. Over the next seven years, experts believe that Lonza Group's EBITDA will grow at a rate of 212.94%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4901 Stock Forecast | FUJIFILM Holdings | Buy |
18
|
¥9.41k | Buy/Sell | ¥10.57k | 9.43% |
UCB Stock Forecast | UCB | Outperform |
18
|
108.65€ | Buy/Sell | 102.66€ | 10.45% |
603259 Stock Forecast | WuXi AppTec | Buy |
18
|
¥54.77 | Buy/Sell | ¥121.48 | 100.84% |
Lonza Group EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Lonza Group's EBIT has decreased from CHF970.00M to CHF880.00M – a 9.28% drop! In the next year, analysts predict that EBIT will jump to CHF1.15B – up 30.14% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 251.06%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
2802 Stock Forecast | Ajinomoto | Outperform |
18
|
¥5.69k | Buy/Sell | ¥6.06k | -3.39% |
LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$218.53 | Buy/Sell | $241.28 | 11.20% |
EMSN Stock Forecast | EMS-CHEMIE HOLDING | Hold |
18
|
CHF619.00 | Buy/Sell | CHF657.14 | 2.91% |
Lonza Group EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Lonza Group's EPS has decreased from CHF14.92 to CHF0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach CHF12.02 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
KRZ Stock Forecast | Kerry Group | Outperform |
18
|
82.00€ | Buy/Sell | 96.27€ | 21.34% |
TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.35 | Buy/Sell | $11.59 | 19.85% |
CRL Stock Forecast | Charles River Laboratories Int... | Outperform |
16
|
$263.09 | Buy/Sell | $229.97 | 1.30% |